T1	Participants 107 166	patients with advanced human immunodeficiency virus disease
T2	Participants 168 272	AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group
T3	Participants 377 417	310 patients entering a controlled trial
